

# **Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020**

<https://marketpublishers.com/r/S551F1D44FDEN.html>

Date: July 2020

Pages: 419

Price: US\$ 2,000.00 (Single User License)

ID: S551F1D44FDEN

## **Abstracts**

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis - Pipeline Review, H2 2020, provides an overview of the Systemic Sclerosis (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 18, 9, 1,

37 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Systemic Sclerosis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Immunology).

The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Systemic Sclerosis (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Systemic Sclerosis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Immunology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Systemic Sclerosis (Scleroderma) - Overview

Systemic Sclerosis (Scleroderma) - Therapeutics Development

Systemic Sclerosis (Scleroderma) - Therapeutics Assessment

Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development

Systemic Sclerosis (Scleroderma) - Drug Profiles

Systemic Sclerosis (Scleroderma) - Dormant Projects

Systemic Sclerosis (Scleroderma) - Discontinued Products

Systemic Sclerosis (Scleroderma) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Accutis Pharmaceuticals Inc, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by AKL Research and Development Ltd, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Allysta Pharmaceuticals Inc, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Amgen Inc, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Anima Biotech Inc, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Aryogen Pharmed Co, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by AstraZeneca Plc, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Atlantic Healthcare Plc, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Aurora Research Institute LLC, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Biomendics LLC, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Blade Therapeutics Inc, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by BriaCell Therapeutics Corp, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Co, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Cantargia AB, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Capella Bioscience Ltd, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Castle Creek Biosciences Inc, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Celdara Medical LLC, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by ChemomAb Ltd, H2 2020

Systemic Sclerosis (Scleroderma) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2020

Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2020

## Systemic Sclerosis (Scleroderma) - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Number of Products by Top 10 Targets, H2 2020  
Number of Products by Stage and Top 10 Targets, H2 2020  
Number of Products by Top 10 Mechanism of Actions, H2 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020  
Number of Products by Routes of Administration, H2 2020  
Number of Products by Stage and Routes of Administration, H2 2020  
Number of Products by Top 10 Molecule Types, H2 2020  
Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

A. Menarini Industrie Farmaceutiche Riunite Srl  
Accutis Pharmaceuticals Inc  
AKL Research and Development Ltd  
Allysta Pharmaceuticals Inc  
Amgen Inc  
AnaMar AB  
Anima Biotech Inc  
arGentis Pharmaceuticals LLC  
Aryogen Pharmed Co  
AstraZeneca Plc  
Atlantic Healthcare Plc  
Aurora Research Institute LLC  
Biogen Inc  
Biomendics LLC  
Blade Therapeutics Inc  
BriaCell Therapeutics Corp  
Bristol-Myers Squibb Co  
Cantargia AB  
Capella Bioscience Ltd  
Castle Creek Biosciences Inc  
Celdara Medical LLC

ChemomAb Ltd  
Chugai Pharmaceutical Co Ltd  
Civi Biopharma Inc  
Corbus Pharmaceuticals Inc  
CSL Ltd  
Cumberland Pharmaceuticals Inc  
Cureveda LLC  
D&D Pharmatech Co Ltd  
Emerald Health Sciences Inc  
Ergon Pharmaceuticals LLC  
FBM Therapeutics LLC  
Forbuis  
Fresenius Kabi SwissBioSim GmbH  
Galapagos NV  
Galecto Biotech AB  
GenKyoTex SA  
Genmab AS  
Gesynta Pharma AB  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
GNI Group Ltd  
H. Lundbeck AS  
Horizon Therapeutics Plc  
iBio Inc  
Ichnos Sciences Inc  
Iltoo Pharma  
ImmuneMed Inc  
Kadmon Corp LLC  
Leadiant Biosciences Inc  
Link Genomics Inc  
MDI Therapeutics Inc  
medac GmbH  
Mitsubishi Tanabe Pharma Corp  
Opsidio LLC  
Panorama Research Inc  
Patagonia Pharmaceuticals LLC  
PDX Pharmaceuticals LLC  
Peptinov SAS  
Pfizer Inc



Processa Pharmaceuticals Inc  
Resolys Bio Inc  
Ribomic Inc  
Riptide Bioscience Inc  
Samumed LLC  
Sanofi  
Seattle Genetics Inc  
Signablok Inc  
StemMed Ltd  
Takeda Pharmaceutical Co Ltd  
Talaris Therapeutics Inc  
Timber Pharmaceuticals Inc  
TRACON Pharmaceuticals Inc  
Tvardi Therapeutics Inc  
Unity Biotechnology Inc  
Vicore Pharma AB  
Viela Bio Inc

## I would like to order

Product name: Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/S551F1D44FDEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S551F1D44FDEN.html>